• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Imago BioSciences Inc.

    1/11/23 9:21:30 AM ET
    $IMGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGO alert in real time by email
    S-8 POS 1 d410590ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on January 11, 2023

    Registration No. 333-258057

    Registration No. 333-263828

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IMAGO BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   45-4915810
    (State or other jurisdiction of incorporation)   (I.R.S. Employer Identification Number)

    2012 Equity Incentive Plan

    2021 Incentive Award Plan

    2021 Employee Stock Purchase Plan

    (Full title of the plan)

     

     

    Kelly E.W. Grez, Secretary

    Imago BioSciences, Inc.

    303 Twin Dolphin Drive, 6th Floor

    Redwood City, California 94065

    (415) 529-5055

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copy to:

    Saee Muzumdar

    Gibson, Dunn & Crutcher LLP

    200 Park Avenue

    New York, NY 10166-0193

    (212) 351-4035

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    TERMINATION OF REGISTRATION

    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a “Registration Statement” and collectively, the “Registration Statements”) filed by Imago BioSciences, Inc. (the “Company”) with the Securities and Exchange Commission:

     

      •  

    Registration No. 333-258057, filed on July 21, 2021, registering 3,171,061 shares of common stock under the Company’s 2012 Equity Incentive Plan, 3,450,000 shares of common stock under the Company’s 2021 Incentive Award Plan, and 350,000 shares of common stock under the Company’s 2021 Employee Stock Purchase Plan.

     

      •  

    Registration No. 333-263828, filed on March 24, 2022, registering 1,676,587 shares of common stock under the Company’s 2021 Incentive Award Plan, and 335,317 shares of common stock under the Company’s 2021 Employee Stock Purchase Plan.

    Pursuant to the Agreement and Plan of Merger, dated as of November 19, 2022 (the “Merger Agreement”), by and among the Company, Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Parent”) and M-Inspire Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statements and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rahway, in the State of New Jersey, on this 11th day of January, 2023.

     

    IMAGO BIOSCIENCES, INC. (REGISTRANT)
    By:  

    /s/ Kelly E.W. Grez

    Name:   Kelly E.W. Grez
    Title:   Secretary

    Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to Registration Statements.

     

    2

    Get the next $IMGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMGO

    DatePrice TargetRatingAnalyst
    10/28/2022$25.00Outperform
    Wedbush
    2/14/2022$37.00Buy
    HC Wainwright & Co.
    8/10/2021$30.00Buy
    Jefferies
    8/10/2021$35.00Buy
    Guggenheim
    8/10/2021Outperform
    Cowen
    8/10/2021$31.00Buy
    Stifel
    More analyst ratings

    $IMGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer

      SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Michael Arenberg to Chief Operating and Business Officer. Mr. Arenberg is a distinguished biopharmaceutical executive who will be charged with leading strategic operations, investor relations, commercial development and business development of Imago. "I welcome Mike to Imago with great enthusiasm at this important stage of company development," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSc

      3/23/22 4:05:00 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Appoints Laurie Keating as Chair of Board of Directors

      BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Directors. "We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focu

      1/19/22 8:00:00 AM ET
      $IMGO
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imago BioSciences Appoints Laurie Keating to Board of Directors

      ​Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021. Keating is a seasoned executive, with nearly two decades of her 40-year career in diverse roles within the biopharmaceutical industry. "I am pleased to welcome to Laurie to Imago's Board of Directors as the company continues to grow, following our successful IPO in July," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. "Laurie brings extensive experience to our Board and we look forward

      11/18/21 4:05:00 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All

      1/11/23 6:45:00 AM ET
      $IMGO
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

      REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatme

      12/20/22 4:05:00 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

      - 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with baseline loss of heterozygosity (LOH) and follow-up samples showed a reduction in homozygous mutant granulocytes and mutant allele frequencies – -Aligned with FDA on strategy for bomedemstat pivotal

      12/12/22 11:30:00 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Keating Laurie

      4 - Imago BioSciences, Inc. (0001623715) (Issuer)

      1/11/23 4:23:43 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tapper Amy E. closing all direct ownership in the company

      4 - Imago BioSciences, Inc. (0001623715) (Issuer)

      1/11/23 4:19:43 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kariuki Enoch

      4 - Imago BioSciences, Inc. (0001623715) (Issuer)

      1/11/23 4:19:47 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Imago BioSciences Inc.

      15-12G - Imago BioSciences, Inc. (0001623715) (Filer)

      1/23/23 7:25:29 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Imago BioSciences Inc.

      EFFECT - Imago BioSciences, Inc. (0001623715) (Filer)

      1/17/23 12:15:09 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Imago BioSciences Inc.

      25-NSE - Imago BioSciences, Inc. (0001623715) (Subject)

      1/11/23 10:41:33 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Imago BioSciences with a new price target

      Wedbush initiated coverage of Imago BioSciences with a rating of Outperform and set a new price target of $25.00

      10/28/22 7:20:34 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Imago BioSciences with a new price target

      HC Wainwright & Co. initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $37.00

      2/14/22 6:06:11 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Imago BioSciences with a new price target

      Jefferies initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $30.00

      8/10/21 8:46:38 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      2/14/23 8:26:45 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      2/1/23 5:16:35 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      1/26/23 8:52:16 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care